Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL29P32 (ribosomal protein L29 pseudogene 32) is a processed pseudogene of the ribosomal protein L29 gene. Pseudogenes are genomic DNA sequences similar to normal genes but are non-functional; they typically do not code for an active protein due to mutation, truncation, or other genomic events[1][5][8]. The canonical ribosomal protein L29 (RPL29) is a constituent of the 60S ribosomal subunit and is involved in protein synthesis, cell proliferation, and development[3][7][9]. However, RPL29P32 itself is a pseudogene and does not encode a functional protein or play a direct role in disease, cell signaling, or therapeutic intervention[1][5][8]. This target is not considered a therapeutic target: it is a processed pseudogene and does not encode an active receptor, enzyme, transporter, or transcription factor. It is not associated with drug interactions, disease roles, molecular functions, or biomarker usage[1][5][8]. If you require structured therapeutic or pharmacological data, you should instead query for the functional protein Ribosomal protein L29 (RPL29), not its pseudogene RPL29P32[3][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L29 pseudogene 32 (RPL29P32).